Raynaud Disease
18
1
1
10
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
22.2%
4 terminated out of 18 trials
71.4%
-15.1% vs benchmark
17%
3 trials in Phase 3/4
30%
3 of 10 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 10 completed trials
Clinical Trials (18)
Metabolomic Analysis of Systemic Sclerosis
Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.
Multi-modal Quantitative Imaging of the Skin
Exparel as a Nerve Block for Severe Hand Pain
Phototherapy For Treatment Of Raynaud's Phenomenon
Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort Study
Effectiveness of Electric Stimulation Therapy in Raynaud's Phenomenon
Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's Phenomenon
A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)
Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud
Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.
PORH and Response to Cold in Raynaud's Phenomenon.
Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) Stimulator
Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in Scleroderma
Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms
Lab Study of MQX-503 in Treatment of Raynaud's
Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic Sclerosis